On one hand, a randomized, placebo‐controlled clinical trial of a B2R antagonist demonstrated some effect on survival in patients with systemic inflammatory response syndrome (Fein et al., 1997). This evidence concerns the gene BDKRB2 and systemic inflammatory response syndrome.